同步放化疗联合rhAd-p53治疗局部进展期宫颈癌的疗效观察  

Efficacy of Concurrent Chemoradiotherapy Combined with rhAd-p53 on Locally Advanced Cervical Cancer

作　　者：董亚勤 许星宇[2] 陈博[2] 杨林[1] DONG Yaqin;XU Xingyu;CHEN Bo;YANG Lin(Department of Radiotherapy,The First Affiliated Hospital of Anhui Medical University,Hefei 230000,China;Department of Gastrointestinal Surgery,The First Affiliated Hospital of Anhui Medical University,Hefei 230000,China)

机构地区：[1]安徽医科大学第一附属医院放疗科,合肥230000 [2]安徽医科大学第一附属医院胃肠外科,合肥230000

出　　处：《肿瘤防治研究》2021年第10期979-982,共4页Cancer Research on Prevention and Treatment

基　　金：安徽省质量工程项目(jyxm0898);安徽医科大学临床科研项目(2020xkj76)。

摘　　要：目的探讨放化疗联合腺病毒重组人p53注射液在局部进展期宫颈癌(LACC)中的近远期疗效。方法采用简单随机分组方法将51例LACC(ⅡA~ⅣA期)患者分为实验组(RCT-p53)24例和对照组(RCT)27例。实验组患者接受rhAd-p53注射液同步放化疗,对照组患者未接受rhAd-p53注射液治疗,放化疗方法同实验组。疗效评价包括近期疗效、远期疗效和早期不良反应。结果RCT-p53组的客观缓解率(ORR)为91.7%,RCT组的ORR为62.9%(P=0.037);两组的完全缓解(CR)率分别为66.7%和40.7%。两组的早期血液学毒性、消化道反应和肝肾功能损伤等不良反应率的差异均无统计学意义。RCT-p53和RCT组的5年无进展生存率(PFS)分别为79.8%和51.3%(P=0.028)。5年生存率(OS)分别为81.6%和60.3%(P=0.061)。结论与同步放化疗相比,加入rhAd-p53治疗有更高的近期疗效和良好的远期生存获益,且不会增加早期不良反应。Objective To analyze the short-and long-term effect of chemoradiotherapy combined with rhAd-p53 on locally advanced cervical cancer(LACC).Methods A total of 51 patients with stageⅡA-ⅣA LACC were divided into experimental group(chemoradiotherapy+rhAd-p53 gene therapy,RCT-p53)and control group(chemoradiotherapy,RCT).Short-term effect,long-term effect and early side-effect were evaluated.Results ORR of RCT-p53 group and RCT group were 91.7% and 62.9%,respectively(P=0.037);CR rates were 66.7% and 40.7%,respectively.There was no significant difference of early side-effects between two groups,in terms of hematologic toxicity,digestive toxicity,hepatotoxicity or renal toxicity.Fiveyear PFS of RCT-p53 group and RCT group were 79.8%and 51.3%,respectively(P=0.028);5-year OS were 81.6% and 60.3%,respectively(P=0.061).Conclusion rhAd-p53 treatment has better short-term effect and long-term effect than concurrent chemoradiotherapy,without increasing early side effects.

关 键 词：宫颈癌 基因治疗 放射治疗 化学治疗 rhAd-p53 

分 类 号：R737.3[医药卫生—肿瘤] R456[医药卫生—临床医学]